Wockhardt Limited announced the approval of its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors, following a review by the Audit Committee, has finalized both standalone and consolidated financial statements. These results, along with the Limited Review Report from MSKC & Associates LLP, have been submitted to the stock exchanges.
Wockhardt Approves Q1 FY27 Financial Results
Wockhardt Limited has officially announced the outcome of its Board of Directors meeting held on August 10, 2026. During this meeting, the Board, after review and approval by the Audit Committee, gave its nod to the company’s unaudited financial results for the first quarter of the financial year 2026-27, which concluded on June 30, 2026. This includes both standalone and consolidated financial statements.
Key Financial Highlights
The accompanying financial statements for the quarter ended June 30, 2026, have been prepared in accordance with Indian Accounting Standard 34 ‘Interim Financial Reporting’ and other recognized accounting principles. The unaudited standalone results show a Profit before tax of ₹107 crore and a Net Profit after tax of ₹107 crore for the quarter. Total income for the standalone segment stood at ₹594 crore. These results were subjected to a limited review by the company’s statutory auditors, MSKC & Associates LLP, whose report is also included.
Consolidated Financial Overview
The consolidated financial statements present a broader financial picture of Wockhardt Limited and its subsidiaries. For the quarter ended June 30, 2026, the consolidated results indicate a Total income of ₹960 crore and a Net Profit after tax of ₹107 crore. The consolidated comprehensive income attributable to equity shareholders was ₹121 crore.
Board Meeting Details
The Board meeting commenced at 1:10 p.m. and concluded at 3:05 p.m. on August 10, 2026. The company confirmed its exclusive engagement in the Pharmaceutical business segment.
Source: BSE
